AMNE (AMNE) Stock Price & Analysis
AMNE (AMNE) rose 0.00% to USD 0 as of June 10, 2026 at 04:55 UTC, according to Nexqual real-time market data.
AMNE last closed at USD 0; the session ranged USD 0–0 on volume of 500,000 shares. Market capitalization is —, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 04:55 UTC.
Key Statistics (as of June 10, 2026 at 04:55 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 500,000 shares |
| Market Cap | — |
| Exchange | PNK |
Technical Analysis (AMNE)
Nexqual's technical model rates AMNE "SELL" based on 0 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 04:55 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 0) |
Analyst Ratings (AMNE)
Wall Street analysts rate AMNE "None", per Nexqual as of June 10, 2026 at 04:55 UTC.
| Consensus Rating | None |
|---|
Earnings (AMNE)
Source: Nexqual, June 10, 2026 at 04:55 UTC.
Financials & Fundamentals (AMNE)
| Total Revenue | $688,172 |
|---|---|
| Revenue Growth (YoY) | -34.60% |
| Gross Margin | -3.44% |
| Operating Margin | -37.80% |
| Profit Margin | -64.83% |
| ROE | -127.59% |
| Current Ratio | 3.02 |
| Total Cash | $80,500 |
| Total Debt | $0 |
| Free Cash Flow | $-502,491 |
Source: Nexqual, June 10, 2026 at 04:55 UTC.
Financial Health Score (AMNE)
Nexqual rates AMNE's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:55 UTC.
| Growth | Critical — Revenue -35% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $81K cash, no debt |
| Cash Flow | Weak — FCF negative: -$502K, burning cash |
| Efficiency | Critical — ROE -128%, ROA -51.9% |
Ownership (AMNE)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 17.52B |
Source: Nexqual, June 10, 2026 at 04:55 UTC.
Leadership (AMNE)
AMNE is led by Terry M. Mixon, Chairman, CEO, COO, CFO, Secretary & Treasurer, per Nexqual as of June 10, 2026 at 04:55 UTC.
| Chairman, CEO, COO, CFO, Secretary & Treasurer | Terry M. Mixon |
|---|---|
| President & Director | Gary Gray |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MGLG | MAGELLAN ENERGY LTD | USD 0 | ▲ 0% |
| HTDS | HARD TO TREAT DISEASES INC | USD 0 | ▲ 0% |
| PHMB | PHARMACOM BIOVET INC | USD 0 | ▲ 0% |
| DLAD | DEALERADVANCE INC | USD 0 | ▲ 0% |
| IGNT | INGEN TECHNOLOGIES INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:55 UTC. This page is informational and not investment advice.